Fourth triMS.online conference

Looking ahead: the future of MS management

The fourth triMS.online conference

21–22 October 2020

14:00-17:00 BST | 09:00-12:00 EDT | 15:00-18:00 CEST

The latest research and clinical insights on Looking ahead: the future of MS management

Themed sessions across two days

  • Day 1 – Tailoring MS treatment in the face of COVID-19
  • Day 2 – Current and emerging treatments for MS

'Hot topic' debates on the topics:

  • COVID-19 will improve the future management of patients with MS
  • Should patients with MS be vaccinated against COVID-19?
  • Can we use anti-CD20 therapies as immune reconstitution therapies rather than maintenance therapies?

About this event

The fourth triMS.online meeting will take place across two days on 21−22 October 2020 on the theme Looking ahead: the future of MS management. Building on the current knowledge of the management of MS during the COVID-19 pandemic, the scientific programme will focus on treatment optimization and how the future of treatment for people with MS will be affected through the role of digital health and emerging therapies.

With a mixture of keynote presentations, plenary lectures, industry symposia and interactive Q&A and debate sessions, the faculty will deep-dive into the latest research and clinical insights across two days:

  • Day 1 - Tailoring MS treatment in the face of COVID-19
  • Day 2 - Current and emerging treatments for MS

We are committed to creating an environment where healthcare professionals and researchers in the field of MS can discuss the latest information and network with fellow professionals free of charge and from the comfort of their home or workplace, without the need to travel.

We welcome the submission of posters for this conference on the following topics:

  • Vaccination in MS
  • Management of MS during the COVID-19 pandemic
  • Effect of comorbidities on treatment effectiveness and disease outcomes in MS
  • Digital health in MS
  • Combination therapy in MS
  • Anti-CD20 therapy in MS
  • Effectiveness of SP1R modulators in MS
  • Plasma cells as a therapeutic target in MS
  • Macrophage manipulation in the treatment and management of MS
  • The use of BTK inhibitors in MS
  • Pregnancy in MS
  • Role of B cells in MS

Visit our ‘Submit a poster’ page to complete the online form and submit your poster for review by the Scientific Steering Committee.

free-registration

Scientific programme (BST)

Day 1 - Tailoring MS treatment in the face of COVID-19

13:30

Conference open

Free time to explore the exhibition stands, poster hall and platinum sponsor theatre

14:00

Welcome

Julia Pakpoor, UK (Chair)

14:05

Live debate

COVID-19 will improve the future management of patients with MS

Julia Pakpoor, UK (Chair)

Gavin Giovannoni, UK

Céline Louapre, France

Douglas Sato, Brazil

 

14:25

Role of immunosuppressive therapies in MS and COVID-19

Gavin Giovannoni, UK

14:35

Impact of COVID-19 on managing pregnancy and MS

Liliana Patrucco, Argentina

 

14:45

Q&A

Julia Pakpoor, UK (Chair)

Gavin Giovannoni, UK

Liliana Patrucco, Argentina

 

14:50

Merck-sponsored satellite symposium

MS management: balancing benefit and risk in a new normal

Klaus Schmierer, UK

Celia Oreja-Guevara, Spain

15:10

Break

Free time to explore the exhibit and poster halls

15:30

The role of digital health in reshaping MS medical services

Ide Smets, UK

15:40

The role of digital health in improving MS monitoring and research

José Flores-Rivera, Mexico

 

15:50

Q&A

Julia Pakpoor (Chair)

José Flores-Rivera, Mexico

Ide Smets, UK

16:05

Roche-sponsored satellite symposium

COVID-19 and MS: can we draw conclusions for clinical practice?

Gavin Giovannoni, UK

16:25

Live debate

Should patients with MS be vaccinated against COVID-19?

Julia Pakpoor, UK (Chair)

Gavin Giovannoni, UK

Saúl Reyes Niño, UK

Lana Zhovtis Ryerson, USA

16:50

Meeting close

Julia Pakpoor, UK (Chair)

Day 2 - Current and emerging treatments for MS

13:30

Conference open

Free time to explore the exhibition stands, poster hall and platinum sponsor theatre

14:00

Welcome

Farrah Mateen, USA (Chair)

14:05

Live debate

Can we use anti-CD20 therapies as immune reconstitution therapies rather than maintenance therapies?

Farrah Mateen, USA (Chair)

Gavin Giovannoni, UK

Monica Marta, UK

Anders Svenningsson, Sweden

14:30

Exploring the potential of BTK inhibitors

Erin Longbrake, USA

 

14:40

Targeting macrophages: a novel therapeutic approach in MS

Claire McCoy, Ireland

14:50

Q&A

Farrah Mateen, USA (Chair)

Claire McCoy, Ireland

 

 

15:05

Break

Free time to explore the exhibit and poster halls

 

15:25

Should we be targeting inthrathecal plasma cells to treat MS?

Sharmilee Gnanapavan

 

15:35

The effectiveness of S1PR modulators: an update

Frauke Zipp

 

15:45

Q&A

Farrah Mateen, USA (Chair)

Sharmilee Gnanapavan, UK

Frauke Zipp, Germany

 

 

16:00

Bristol Myers Squibb-sponsored satellite symposium

Quantitative brain volume assessment: past, present, and future

Michael G. Dwyer, USA

 

16:20

Live discussion

The future of combination therapies in MS

Farrah Mateen, USA (Chair)

Gavin Giovannoni, UK

Jorge Correale, Argentina

Anna Williams, UK

 

16:50

Meeting close

Farrah Mateen, USA (Chair)